Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Safety of MGMT Gene Transfer into Hematopoietic Progenitors: A Phase I Clinical Trial Using Retroviral Gene Transfer of G156A MGMT To Protect Hematopoiesis during BG Plus Alkylating Agent Treatment of Advanced Malignancies.

Jane S. Reese, Karen T. Lingas, Colin L. Sweeney, Joanna M. Brell, Stanton L. Gerson

Blood (2007) 110 (11): 500.

https://doi.org/10.1182/blood.V110.11.500.500

Published: 2007

Journal Articles

Improved Culture Expansion of Human Mesenchymal Stem Cells (MSCs) Using Fibroblastic Growth Factor-2 for the Treatment of Graft Versus Host Disease (GVHD).

Jane S. Reese, Luis A. Solchaga, Karen T. Lingas, Hillard M. Lazarus, Stanton L. Gerson

Blood (2007) 110 (11): 1207.

https://doi.org/10.1182/blood.V110.11.1207.1207

Published: 2007

Journal Articles

Retrovirus Insertion Site Analysis Following In Vivo Drug Selection in a Phase I Clinical Trial Utilizing G156A MGMT for Enhanced Chemotherapy of Advanced Malignancies.

Colin L. Sweeney, Karen Lingas, Jane S. Reese, Susan Flick, Stanton L. Gerson

Blood (2005) 106 (11): 3048.

https://doi.org/10.1182/blood.V106.11.3048.3048

Published: 2005

Journal Articles

Progressive Emergence of a Dominant Unit during Dual Unit Umbilical Cord Blood (UCB) Culture.

Min Liu, Jane S. Reese, Jennifer J. Jaroscak, MD, Stanton L. Gerson, MD

Blood (2005) 106 (11): 2191.

https://doi.org/10.1182/blood.V106.11.2191.2191

Published: 2005

Journal Articles

Drug Selection Enrichment of Type II Pneumocytes Following Transplant of P140K MGMT Lentiviral Transduced Hematopoietic Stem Cells.

Jane S. Reese, Justin C. Roth, Stanton L. Gerson

Blood (2004) 104 (11): 3594.

https://doi.org/10.1182/blood.V104.11.3594.3594

Published: 2004

Journal Articles

Repopulating defect of mismatch repair–deficient hematopoietic stem cells

Jane S. Reese, Lili Liu, Stanton L. Gerson

Blood (2003) 102 (5): 1626–1633.

https://doi.org/10.1182/blood-2002-10-3035

Published: 2003

NARROW

Safety of MGMT Gene Transfer into Hematopoietic Progenitors: A Phase I Clinical Trial Using Retroviral Gene Transfer of G156A MGMT To Protect Hematopoiesis during BG Plus Alkylating Agent Treatment of Advanced Malignancies.

Improved Culture Expansion of Human Mesenchymal Stem Cells (MSCs) Using Fibroblastic Growth Factor-2 for the Treatment of Graft Versus Host Disease (GVHD).

Retrovirus Insertion Site Analysis Following In Vivo Drug Selection in a Phase I Clinical Trial Utilizing G156A MGMT for Enhanced Chemotherapy of Advanced Malignancies.

Progressive Emergence of a Dominant Unit during Dual Unit Umbilical Cord Blood (UCB) Culture.

Drug Selection Enrichment of Type II Pneumocytes Following Transplant of P140K MGMT Lentiviral Transduced Hematopoietic Stem Cells.

Repopulating defect of mismatch repair–deficient hematopoietic stem cells

Email alerts

ASH Publications

American Society of Hematology

Safety of MGMT Gene Transfer into Hematopoietic Progenitors: A Phase I Clinical Trial Using Retroviral Gene Transfer of G156A MGMT To Protect Hematopoiesis during BG Plus Alkylating Agent Treatment of Advanced Malignancies.

Improved Culture Expansion of Human Mesenchymal Stem Cells (MSCs) Using Fibroblastic Growth Factor-2 for the Treatment of Graft Versus Host Disease (GVHD).

Retrovirus Insertion Site Analysis Following In Vivo Drug Selection in a Phase I Clinical Trial Utilizing G156A MGMT for Enhanced Chemotherapy of Advanced Malignancies.

Progressive Emergence of a Dominant Unit during Dual Unit Umbilical Cord Blood (UCB) Culture.

Drug Selection Enrichment of Type II Pneumocytes Following Transplant of P140K MGMT Lentiviral Transduced Hematopoietic Stem Cells.

Repopulating defect of mismatch repair–deficient hematopoietic stem cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only